| Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometeric analysis - BioAssay Summary (##)-2-Fluoro-2-(2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid (2a) has been prepared and subjected to biological testing against all three subtypes of the PPARs. This compound exhibited agonist effects with EC(50) values of 560 and 55 nM against PPAR## and PPAR##, respectively, in a luciferase assay. Moreover, compound (##)-2a also exhibited more .. |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target BioActive Compounds: 4 Description: Title: Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516. Abstract: (##)-2-Fluoro-2-(2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid (2a) has been prepared and subjected to biological testing against all three subtypes of the PPARs. This compound exhibited agonist effects with EC(50) values of 560 and 55 nM against PPAR## and PPAR##, respectively, in a luciferase assay. Moreover, compound (##)-2a also exhibited potent ability to induce oleic acid oxidation in a human myotube cell assay with EC(50)=3.7 nM. Compound (##)-2a can be classified as a dual PPAR##/## agonist with a 10-fold higher potency against the PPAR## receptor than against the PPAR## receptor. Molecular modeling studies revealed that both enantiomers of 2a bind to the PPAR## receptor with similar binding energies. (PMID: 22051054) Comment Compounds with activity <= 50uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation. Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 12227 ChEMBL target type: Target is a single protein chain Result Definitions
* Activity Concentration. Data Table (Concise) Classification
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||